Glucose-6-phosphate dehydrogenase deficiency screening: Difference between revisions
No edit summary |
No edit summary |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
{{CMG}}; {{AE}} {{MA}} | {{CMG}}; {{AE}} {{MA}} | ||
==Overview== | ==Overview== | ||
G6PD defeciency screening in [[neonates]] is done routinly in some regions with high [[incidence]]. | |||
==Screening== | ==Screening== | ||
G6PD defeciency screening in neonates is done routinly in some regions with high incidence. <ref name="pmid19177059">{{cite journal |vauthors=Kaplan M, Hammerman C |title=The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective |journal=J Perinatol |volume=29 Suppl 1 |issue= |pages=S46–52 |date=February 2009 |pmid=19177059 |doi=10.1038/jp.2008.216 |url=}}</ref> | *G6PD defeciency screening in neonates is done routinly in some regions with high [[incidence]]. <ref name="pmid19177059">{{cite journal |vauthors=Kaplan M, Hammerman C |title=The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective |journal=J Perinatol |volume=29 Suppl 1 |issue= |pages=S46–52 |date=February 2009 |pmid=19177059 |doi=10.1038/jp.2008.216 |url=}}</ref> | ||
*Screening test is quantitative laboratory assay for G6PD enzyme activity. | |||
Screening is done before giving oxidant medication to high risk patients. | *Screening is done before giving [[oxidant]] medication to high risk patients. | ||
*There is insufficient evidence to recommend routine screening for G6PD deficiency. | |||
There is insufficient evidence to recommend routine screening for | |||
==References== | ==References== | ||
| Line 36: | Line 18: | ||
{{WS}} | {{WS}} | ||
[[Category: (name of the system)]] | [[Category: (name of the system)]] | ||
Latest revision as of 18:41, 25 October 2018
|
Glucose-6-phosphate dehydrogenase deficiency Microchapters |
|
Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glucose-6-phosphate dehydrogenase deficiency screening On the Web |
|
American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency screening |
|
FDA on Glucose-6-phosphate dehydrogenase deficiency screening |
|
CDC on Glucose-6-phosphate dehydrogenase deficiency screening |
|
Glucose-6-phosphate dehydrogenase deficiency screening in the news |
|
Blogs on Glucose-6-phosphate dehydrogenase deficiency screening |
|
Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency |
|
Risk calculators and risk factors for Glucose-6-phosphate dehydrogenase deficiency screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahda Alihashemi M.D. [2]
Overview
G6PD defeciency screening in neonates is done routinly in some regions with high incidence.
Screening
- G6PD defeciency screening in neonates is done routinly in some regions with high incidence. [1]
- Screening test is quantitative laboratory assay for G6PD enzyme activity.
- Screening is done before giving oxidant medication to high risk patients.
- There is insufficient evidence to recommend routine screening for G6PD deficiency.
References
- ↑ Kaplan M, Hammerman C (February 2009). "The need for neonatal glucose-6-phosphate dehydrogenase screening: a global perspective". J Perinatol. 29 Suppl 1: S46–52. doi:10.1038/jp.2008.216. PMID 19177059.